Grifols Moves Deeper Into Proteome R&D With $146M Deal for Alkahest
Summary
Three years later, Grifols reached a $1.9 billion deal to acquire the nucleic acid testing donor screening business of Marlborough, MA-based Hologic (NASDAQ: HOLX). The California biotech brought to the alliance its proteome expertise, which yielded therapeutic candidates addressing cognitive decline in aging and other central nervous system disorders, including Alzheimer’s. The two most advanced Alkahest drug candidates, GRF-6019 and GRF-6021, are intended to enhance the growth and development of nerve tissue, improve the deficits in learning and memory that come with aging, and reduce neuroinflammation. The company’s pipeline also includes AKST4290, in mid-stage tests for the wet form of age-related macular degeneration as well as Parkinson’s, and AKST1210, which is in Phase 2 development for treating cognitive impairment related to end-stage renal disease. “We saw the promise of Alkahest’s understanding of aging when we made our first investment and entered into a collaboration agreement with them five years ago,” Víctor Grífols, co-CEO of Grifols, said in a prepared statement.
Classifications
AskAI Classifications
LabelsLinked Companies
